Complex Carbohydrate Spheres Protect Islet Cells; Allow Them To Function Properly

November 08, 1997

DALLAS -- Duke University Medical Center researchers have developed special spheres to protect insulin-producing pancreatic islet cells, an achievement they feel improves the possibility of islet cell transplantation as a viable treatment for diabetes.

The development of these spheres, which are formed from a complex carbohydrate known as alginate, appears to solve one of the major problems hindering successful islet cell transplants.

"These spheres have pores that are large enough to allow glucose to enter and insulin to exit, but are small enough to keep immune system cells from entering the spheres and attacking the islet cells," said Emmanuel Opara, assistant research professor of experimental surgery, who heads Duke's islet cell research.

The researchers also found that when tested in experimental animal models, the isolated islet cells produced insulin appropriately in response to changes in glucose levels.

The results of the Duke research were prepared for presentation Saturday (Nov. 8) at the 31st annual meeting of the Association for Academic Surgery in Dallas by Opara and Dr. Marc Garfinkel, former surgical fellow at Duke and now at the University of California at San Diego.

Insulin, a hormone produced and secreted by specialized cells in the pancreas called islets of Langerhans, converts sugars, starches and other foods into the energy needed for everyday life. These islets do not function properly in insulin-dependent, or Type I, diabetes. These patients must inject insulin to stave off the long-term effects of the disease, which include blindness, kidney disease, nerve damage, limb loss and potentially death.

The experimental islet cells are isolated from a donor animal pancreas by treating the gland with enzymes that digest all tissue except islet cells. The isolated cells are then added to an alginate solution.

Using a Duke-developed droplet generator, the alginate solution is forced through a fine needle, creating tiny spheres that harden as they drop into a calcium solution. Each sphere usually contains one or two cells, Opara said. At this point in the process, the entire sphere is a solid. The spheres are then coated with an outer layer of alginate, separated by an amino acid layer.

"We then chemically treat the spheres, in a process called chelation, causing the initial layer of alginate to liquefy," Opara said. "The liquid center provides an ideal environment for the islets to function within a protective shell."

The researchers tested the ability of these islets to secrete the appropriate amounts of insulin when challenged with different levels of glucose in three settings: one group with liquefied sphere cores, the second group with unliquefied cores, and third group with islets that had been cultured for 24 hours in a solution of nutrients and antibiotics, but without a liquefied core.

"The islets in the first group responded as normal islet cells would in response to changing glucose levels, while the second group showed no response at all," Opara said. "The third group showed a small, but significant response, which leads us to believe that culturing may enhance their function."

Surgeons have transplanted more than 7,000 human pancreases since 1966, which has permitted many diabetics to stop injecting insulin, but there are not nearly enough organs to go around. It is estimated that more than 1 million Americans with Type I diabetes could benefit immediately from such a transplant; however, only about 5,000 pancreases become available each year for transplantation.

Scientists developed the method for isolating islet cells in the late 1960s. Since then, about 200 procedures have been performed; however, in many of the patients, the islets stopped working and the patients returned to injectable insulin.

The chemical process employed to isolate the islets can take as many as three to four human pancreases to provide the approximately 1 million islet cells needed to survive transplant. For this reason, researchers have looked to other sources for islet cells.

Pigs are an attractive source of islets, said Duke's Dr. Robert Harland, transplant surgeon and member of the research team, since more than 90 million are killed each year for food. Researchers at Duke are working with specially bred pigs with human genes inserted into their genetic make-up, believing that when the tissue is transplanted into humans, it will escape detection by the immune system.

Harland said that while further tests are needed to better understand potential immune response issues and the optimum site in the body to implant the cells, islet cell transplants could become a clinical reality in the near future.

"Surgically, we would probably place the cells laparoscopically somewhere in the abdomen, which is much less invasive than a pancreas transplant," Harland explained. "At this point, we don't know how long the islets would continue to function. But if we needed to implant new cells every six months to a year, that would still be better for the patient than injecting insulin multiple times during the day.

"Research has shown how important close control of glucose levels is for diabetics in preventing the negative outcomes of the disease," Harland said. "Islet cell transplants have the potential to provide this level of glucose control."

Harland predicted that the likely first patients to receive such transplants will be Type I diabetics with a functioning kidney transplant since they will already be on anti-rejection medication.

A majority of Type II diabetics are not candidates for islet cell transplants, since the root of their disorder is not improper production of insulin, but rather the ability of receptors in the body to properly process insulin.

Duke's islet cell research is currently being supported by its department of surgery.
-end-


Duke University Medical Center

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.